Who are Lumena Pharmaceuticals's investors?

Lumena Pharmaceuticals's investors include Frazier Life Sciences, Longitude Capital, Oberland Capital, Pappas Capital, RiverVest Venture Partners, Sanofi Ventures.

How much funding has Lumena Pharmaceuticals raised?

Lumena Pharmaceuticals has disclosed $48M raised across 2 rounds.

Who acquired Lumena Pharmaceuticals?

Lumena Pharmaceuticals was acquired by Shire.

Where is Lumena Pharmaceuticals headquartered?

Lumena Pharmaceuticals is headquartered in Durham, US.

Lumena Pharmaceuticals

acquired by Shire

Durham, US · Founded 2018 · 494 employees on LinkedIn · 6 known investors

Find your way into Lumena Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Lumena Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Shire in 2014 (now part of Takeda).

Biotech Medical Devices

Founders & leadership

John McKearnNamed on SEC filing

Edward E. GreeneNamed on SEC filing

Rosina Maar PaviaNamed on SEC filing

Ford S. WorthyNamed on SEC filing

Michael GreyNamed on SEC filing

Investors · 6

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: the VCSheet dataset · Not right? Tell us

Oberland Capitallisted by Oberland CapitalNew York

Pappas Capitallisted by Pappas CapitalDurham

RiverVest Venture Partnerslisted by RiverVest Venture PartnersSt. Louis · $500K – $3M

How we know: RiverVest Venture Partners's portfolio page · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$48M disclosed across 2 rounds · 2011–2014

▶$45.5MraisedMar 2014 · 13 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Alejandro DorenbaumExecutive Officer
Howard E. GreeneDirector
Michael GreyExecutive Officer, Director
David R. SavelloDirector
Susan E. DubeExecutive Officer
Alana B. McNultyExecutive Officer
John P. McKearnDirector
Edward MathersDirector
Robert AlexanderDirector
Bradley T. KellerExecutive Officer
Ciara KennedyExecutive Officer

Offering amount: $45.5M
Amount sold: $45.5M
First sale: Mar 2014
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.5MraisedFeb 2012 · 6 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

John McKearnDirector
Edward E. GreeneDirector
Rosina Maar PaviaDirector
Ford S. WorthyExecutive Officer
Michael GreyExecutive Officer, Director

Offering amount: $2.5M
Amount sold: $2.5M
First sale: Feb 2011
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Lumena Pharmaceuticals do?: Acquired by Shire in 2014 (now part of Takeda).
Who are Lumena Pharmaceuticals's investors?: Lumena Pharmaceuticals's investors include Frazier Life Sciences, Longitude Capital, Oberland Capital, Pappas Capital, RiverVest Venture Partners, Sanofi Ventures.
How much funding has Lumena Pharmaceuticals raised?: Lumena Pharmaceuticals has disclosed $48M raised across 2 rounds.
Who acquired Lumena Pharmaceuticals?: Lumena Pharmaceuticals was acquired by Shire.
Where is Lumena Pharmaceuticals headquartered?: Lumena Pharmaceuticals is headquartered in Durham, US.